Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and DLI Maintenance in Ph- Negative B-ALL
NCT07105579Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Aug 2025; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07105579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105579.